AR047218A1 - Compuestos heterociclicos fusionados que contienen pirrol y pirazol,utiles en el tratamiento de enfermedades mediadas por serotonina, composiciones farmaceuticas que los contienen, usos y metodos de preparacion - Google Patents
Compuestos heterociclicos fusionados que contienen pirrol y pirazol,utiles en el tratamiento de enfermedades mediadas por serotonina, composiciones farmaceuticas que los contienen, usos y metodos de preparacionInfo
- Publication number
- AR047218A1 AR047218A1 ARP040103363A ARP040103363A AR047218A1 AR 047218 A1 AR047218 A1 AR 047218A1 AR P040103363 A ARP040103363 A AR P040103363A AR P040103363 A ARP040103363 A AR P040103363A AR 047218 A1 AR047218 A1 AR 047218A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally
- ring
- substituted
- carbon
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 22
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 18
- 125000004432 carbon atom Chemical group C* 0.000 abstract 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 11
- 150000001721 carbon Chemical group 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 6
- 125000004076 pyridyl group Chemical group 0.000 abstract 6
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- 125000001931 aliphatic group Chemical group 0.000 abstract 4
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000002950 monocyclic group Chemical group 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- -1 -OH Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000001544 thienyl group Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 abstract 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000005724 cycloalkenylene group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000005289 uranyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50452803P | 2003-09-17 | 2003-09-17 | |
| US55267304P | 2004-03-11 | 2004-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047218A1 true AR047218A1 (es) | 2006-01-11 |
Family
ID=34526458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103363A AR047218A1 (es) | 2003-09-17 | 2004-09-17 | Compuestos heterociclicos fusionados que contienen pirrol y pirazol,utiles en el tratamiento de enfermedades mediadas por serotonina, composiciones farmaceuticas que los contienen, usos y metodos de preparacion |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US7402680B2 (enExample) |
| EP (1) | EP1668014B1 (enExample) |
| JP (1) | JP5069907B2 (enExample) |
| KR (1) | KR101151653B1 (enExample) |
| CN (1) | CN103788089A (enExample) |
| AR (1) | AR047218A1 (enExample) |
| AT (1) | ATE420881T1 (enExample) |
| AU (1) | AU2004283196B2 (enExample) |
| BR (1) | BRPI0414541B8 (enExample) |
| CA (1) | CA2539426C (enExample) |
| CL (1) | CL2009000943A1 (enExample) |
| CR (1) | CR8302A (enExample) |
| CY (1) | CY1109416T1 (enExample) |
| DE (1) | DE602004019118D1 (enExample) |
| DK (1) | DK1668014T3 (enExample) |
| EA (2) | EA200801812A1 (enExample) |
| EC (1) | ECSP066436A (enExample) |
| ES (1) | ES2319539T3 (enExample) |
| IL (2) | IL174283A (enExample) |
| IS (1) | IS2756B (enExample) |
| MX (1) | MXPA06003150A (enExample) |
| NI (1) | NI200600094A (enExample) |
| NZ (1) | NZ545836A (enExample) |
| PL (1) | PL1668014T3 (enExample) |
| PT (1) | PT1668014E (enExample) |
| SG (1) | SG146683A1 (enExample) |
| SI (1) | SI1668014T1 (enExample) |
| TW (1) | TWI345565B (enExample) |
| WO (1) | WO2005040169A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06003150A (es) * | 2003-09-17 | 2006-08-31 | Johnson & Johnson | Compuestos heterociclicos fusionados. |
| WO2005079845A1 (ja) * | 2004-02-20 | 2005-09-01 | Astellas Pharma Inc. | 片頭痛予防薬 |
| ES2398694T3 (es) | 2004-06-30 | 2013-03-21 | Athersys, Inc. | Derivados de azepina sustituidos como moduladores de receptores de serotonina |
| WO2006066133A2 (en) | 2004-12-16 | 2006-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20080171788A1 (en) * | 2005-02-08 | 2008-07-17 | Shinobu Akuzawa | Medicament For Irritable Bowel Syndrome |
| US7642253B2 (en) | 2005-05-11 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| GB0513886D0 (en) * | 2005-07-06 | 2005-08-10 | Glaxo Group Ltd | Novel compounds |
| KR101353268B1 (ko) * | 2005-08-04 | 2014-02-06 | 얀센 파마슈티카 엔.브이. | 세로토닌 수용체 모듈레이터로서의 피리미딘 화합물 |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| CA2617473A1 (en) * | 2005-08-08 | 2007-02-15 | Astellas Pharma Inc. | Acylguanidine derivative or salt thereof |
| AU2007207508B2 (en) * | 2006-01-19 | 2011-08-18 | Athersys, Inc. | Thiophenyl and pyrrolyl azepines as serotonin 5-HT2c receptor ligands and uses thereof |
| WO2007112402A1 (en) * | 2006-03-27 | 2007-10-04 | Janssen Pharmaceutica N.V. | Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators |
| CN101479252B (zh) * | 2006-05-05 | 2014-01-29 | 詹森药业有限公司 | 用于制备含吡唑的化合物的方法 |
| CN101511833A (zh) * | 2006-08-28 | 2009-08-19 | 埃科特莱茵药品有限公司 | 1,4,5,6,7,8-六氢-1,2,5-三氮杂-甘菊环烃衍生物 |
| WO2009058810A1 (en) * | 2007-11-02 | 2009-05-07 | Janssen Pharmaceutica N.V. | Process for the preparation of substituted 2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene derivatives |
| EP2229361A1 (en) * | 2008-01-03 | 2010-09-22 | Allergan, Inc. | Tetrahydroindoles having sphingosine-1-phosphate receptor activity |
| US8829011B2 (en) | 2008-10-29 | 2014-09-09 | Janssen Pharmaceutica Nv | 2-aminopyrimidine compounds as serotonin receptor modulators |
| EP2358714B1 (en) | 2008-11-18 | 2012-08-01 | F. Hoffmann-La Roche AG | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes |
| WO2010060854A1 (en) * | 2008-11-25 | 2010-06-03 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents |
| US8492374B2 (en) * | 2009-04-29 | 2013-07-23 | Industrial Technology Research Institute | Azaazulene compounds |
| GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| AU2012244846B2 (en) | 2011-04-21 | 2016-07-07 | Basf Se | Novel pesticidal pyrazole compounds |
| AU2011376717A1 (en) | 2011-09-14 | 2014-03-20 | Proximagen Limited | New enzyme inhibitor compounds |
| WO2013156318A1 (en) | 2012-04-16 | 2013-10-24 | Basf Se | Substituted pesticidal pyrazole compounds |
| ES2800288T3 (es) | 2012-06-20 | 2020-12-29 | Basf Se | Mezclas plaguicidas que comprenden un compuesto de pirazol |
| CN104936960B (zh) * | 2012-08-16 | 2016-12-28 | 詹森药业有限公司 | 作为n型钙通道阻滞剂的吡咯并吡唑 |
| WO2014063942A1 (en) | 2012-10-23 | 2014-05-01 | Basf Se | Substituted pesticidal pyrazole compounds |
| CA2894552A1 (en) | 2012-12-21 | 2014-06-26 | Abt Holding Company | Benzazepines as serotonin 5-ht2c receptor ligands and uses thereof |
| US9309262B2 (en) | 2013-03-13 | 2016-04-12 | Abt Holding Company | Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof |
| US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
| WO2015055497A1 (en) | 2013-10-16 | 2015-04-23 | Basf Se | Substituted pesticidal pyrazole compounds |
| ES2911293T3 (es) * | 2014-11-21 | 2022-05-18 | Akarna Therapeutics Ltd | Compuestos bicíclicos fusionados para el tratamiento de enfermedades |
| CA2975997A1 (en) * | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
| CN105503647A (zh) * | 2015-12-10 | 2016-04-20 | 苏州昊帆生物科技有限公司 | 环丙基肼盐酸盐的制备方法 |
| US9951039B2 (en) * | 2016-04-08 | 2018-04-24 | The Hong Kong Polytechnic University | Pyrimidines for treatment of bacterial infections |
| KR101917264B1 (ko) * | 2016-12-22 | 2018-11-13 | 한국과학기술연구원 | 5-ht7 수용체 조절제로 작용하는 아제핀 유도체 |
| KR102037494B1 (ko) | 2017-12-11 | 2019-10-28 | 씨제이헬스케어 주식회사 | 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법 |
| WO2019137995A1 (en) | 2018-01-11 | 2019-07-18 | Basf Se | Novel pyridazine compounds for controlling invertebrate pests |
| CN112300169B (zh) * | 2019-07-26 | 2022-03-04 | 上海美迪西生物医药股份有限公司 | 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用 |
| KR20190120112A (ko) | 2019-10-08 | 2019-10-23 | 씨제이헬스케어 주식회사 | 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법 |
| WO2021145655A1 (ko) * | 2020-01-13 | 2021-07-22 | 압타바이오 주식회사 | 신규한 피라졸 유도체 |
| WO2021155841A1 (en) | 2020-02-07 | 2021-08-12 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024169952A1 (en) | 2023-02-16 | 2024-08-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1197466B (de) | 1962-03-22 | 1965-07-29 | Thomae Gmbh Dr K | Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen |
| US3312716A (en) | 1964-08-11 | 1967-04-04 | Aldrich Chem Co Inc | 4-hydroxy-3-pyrrolidinemethanols |
| GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| US4314081A (en) | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| GB1484140A (en) | 1974-04-24 | 1977-08-24 | Wyeth John & Brother Ltd | Pyrrolopyridine derivatives |
| US3969355A (en) | 1974-11-01 | 1976-07-13 | Morton-Norwich Products, Inc. | 5-Aminoethyl-2,4-diphenylpyrimidine dihydrobromide |
| GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| DK27383A (da) | 1982-02-17 | 1983-08-18 | Lepetit Spa | Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner |
| US4673405A (en) | 1983-03-04 | 1987-06-16 | Alza Corporation | Osmotic system with instant drug availability |
| US4576604A (en) | 1983-03-04 | 1986-03-18 | Alza Corporation | Osmotic system with instant drug availability |
| US4857330A (en) | 1986-04-17 | 1989-08-15 | Alza Corporation | Chlorpheniramine therapy |
| JPH03148265A (ja) | 1989-11-01 | 1991-06-25 | Sumitomo Chem Co Ltd | ５，７―ジフェニル―４，６―ジアザインダン誘導体、その製造法およびそれを有効成分とする除草剤 |
| US5137890A (en) * | 1990-02-14 | 1992-08-11 | Ortho Pharmaceutical Corporation | 4-phenyl tetrahydropyrido(4,3-d)pyrimidines |
| US5053508A (en) | 1990-03-09 | 1991-10-01 | American Home Products Corporation | Fused heterotricyclic imides with psychotropic activity and intermedrates thereof |
| US5648352A (en) | 1991-09-13 | 1997-07-15 | Merck & Co., Inc. | Piperazinylcamphorsulfonyl oxytocin antagonists |
| WO1994014777A1 (en) | 1992-12-28 | 1994-07-07 | Eisai Co., Ltd. | Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar) |
| US6677310B1 (en) | 1999-04-21 | 2004-01-13 | Nabi | Ring-expanded nucleosides and nucleotides |
| US5843912A (en) | 1994-07-06 | 1998-12-01 | Universy Of Maryland | Ring-expanded nucleosides and nucleotides |
| US5405848A (en) | 1993-12-22 | 1995-04-11 | Ortho Pharmaceutical Corporation | Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors |
| US5663178A (en) * | 1995-02-06 | 1997-09-02 | Eli Lilly And Company | Tetrahydro-beta carbolines |
| WO1995029909A1 (en) | 1994-04-29 | 1995-11-09 | Pfizer Inc. | Novel acyclic and cyclic amides as neurotransmitter release enhancers |
| AU5317996A (en) | 1995-04-18 | 1996-11-07 | Eli Lilly And Company | Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor |
| EP0883613A1 (en) | 1996-02-09 | 1998-12-16 | Smithkline Beecham Plc | Sulfonamide derivatives as 5ht7 receptor antagonists |
| TW470745B (en) | 1996-05-23 | 2002-01-01 | Janssen Pharmaceutica Nv | Hexahydro-pyrido[4,3-b]indole derivatives |
| JP3531169B2 (ja) | 1996-06-11 | 2004-05-24 | 三菱ウェルファーマ株式会社 | 縮合ヘテロ環化合物およびその医薬用途 |
| GB9612884D0 (en) | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
| US6025367A (en) | 1996-06-25 | 2000-02-15 | Smithkline Beecham Plc | Sulfonamide derivatives as 5HT7 receptor antagonists |
| JP4076234B2 (ja) | 1996-06-28 | 2008-04-16 | 明治製菓株式会社 | テトラヒドロベンズインドール化合物 |
| GB9700899D0 (en) | 1997-01-17 | 1997-03-05 | Smithkline Beecham Plc | Novel treatment |
| US6177443B1 (en) | 1997-03-07 | 2001-01-23 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use |
| AU6290998A (en) | 1997-03-07 | 1998-09-29 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use |
| EP0905136A1 (en) * | 1997-09-08 | 1999-03-31 | Janssen Pharmaceutica N.V. | Tetrahydro gamma-carbolines |
| US5951518A (en) | 1997-10-31 | 1999-09-14 | Teleflex, Incorporated | Introducing device with flared sheath end |
| AU1558899A (en) | 1997-11-10 | 1999-05-31 | F. Hoffmann-La Roche Ag | Isoquinoline derivatives for use against cns disorders |
| WO1999054303A1 (en) | 1998-04-22 | 1999-10-28 | Meiji Seika Kaisha, Ltd. | Optically active tetrahydrobenzindole derivatives |
| WO1999061027A1 (en) | 1998-05-22 | 1999-12-02 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
| US5997905A (en) | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
| WO2000024399A1 (en) | 1998-10-23 | 2000-05-04 | Sepracor Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| US6245785B1 (en) | 1998-11-30 | 2001-06-12 | Warner Lambert Company | Dissolution of triprolidine hydrochloride |
| GB9828004D0 (en) | 1998-12-18 | 1999-02-10 | Smithkline Beecham Plc | Use |
| GB9906624D0 (en) | 1999-03-23 | 1999-05-19 | Smithkline Beecham Plc | Novel compounds |
| CZ20013465A3 (cs) | 1999-04-01 | 2002-10-16 | Pfizer Products Inc. | Aminopyrimidiny jako inhibitory sorbitoldehydrogenasy |
| GB9912701D0 (en) | 1999-06-01 | 1999-08-04 | Smithkline Beecham Plc | Novel compounds |
| CN1238343C (zh) | 1999-09-09 | 2006-01-25 | 组合化学工业株式会社 | 嘧啶衍生物及含有该衍生物的除草剂 |
| WO2001029029A1 (en) | 1999-10-18 | 2001-04-26 | Smithkline Beecham P.L.C. | Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists |
| UA77650C2 (en) | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| WO2001057039A1 (en) | 2000-02-04 | 2001-08-09 | Wyeth | Pyrrolo-isoquinoline and tetrahydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-ht7 receptor |
| EP1264820A4 (en) | 2000-03-14 | 2004-09-15 | Fujisawa Pharmaceutical Co | amide compounds |
| US6586469B2 (en) | 2000-07-25 | 2003-07-01 | Medpointe Healthcare Inc. | Antihistaminic/antitussive compositions |
| ES2281434T3 (es) | 2000-08-14 | 2007-10-01 | Ortho-Mcneil Pharmaceutical, Inc. | Pirazoles sustituidos. |
| CZ2003635A3 (cs) * | 2000-09-06 | 2004-12-15 | Ortho Mcneil Pharmaceutical, Inc. | Substituovaný pyrazol a jeho použití |
| US20040267010A1 (en) | 2001-02-02 | 2004-12-30 | Forbes Ian Thomson | Sulfonamide compounds, their preparation and use |
| DE60214138T2 (de) * | 2001-02-21 | 2007-03-29 | Janssen Pharmaceutica N.V. | Isoxazolin-derivate als antidepressiva |
| DE10111842A1 (de) | 2001-03-13 | 2002-09-19 | Boehringer Ingelheim Pharma | Antithrombotische Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel |
| US20020183519A1 (en) | 2001-03-13 | 2002-12-05 | Herbert Nar | Antithrombotic carboxylic acid amides |
| US6559174B2 (en) | 2001-03-20 | 2003-05-06 | Merck & Co., Inc. | N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors |
| US6806380B2 (en) | 2001-10-02 | 2004-10-19 | Lexicon Pharmaceuticals, Inc. | Modified safe and efficient process for the environmentally friendly synthesis of imidoesters |
| IL161576A0 (en) * | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| US6806279B2 (en) | 2001-12-17 | 2004-10-19 | Sunesis Pharmaceuticals, Inc. | Small-molecule inhibitors of interleukin-2 |
| SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| US20030199544A1 (en) | 2002-04-18 | 2003-10-23 | Woods Keith W. | Farnesyltransferase inhibitors |
| US20030199542A1 (en) | 2002-04-18 | 2003-10-23 | Woods Keith W. | Farnesyltransferase inhibitors |
| HRP20020452A2 (en) | 2002-05-23 | 2004-02-29 | Pliva D D | 1,2-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof |
| CA2487679A1 (en) * | 2002-05-30 | 2003-12-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of jak and cdk2 protein kinases |
| US20050288355A1 (en) | 2002-06-20 | 2005-12-29 | Arne Mork | Combination therapy wherein a serotonin reuptake inhibitor is used |
| CA2493637A1 (en) | 2002-07-25 | 2004-02-12 | Manuela Villa | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| WO2004014374A1 (en) | 2002-07-25 | 2004-02-19 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| WO2004011467A1 (ja) | 2002-07-29 | 2004-02-05 | Hokko Chemical Industry Co., Ltd. | トリアゾロピリミジン誘導体および農園芸用殺菌剤 |
| US20040121010A1 (en) | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| EP1556360B1 (en) | 2002-10-30 | 2008-01-23 | Ciba SC Holding AG | Electroluminescent device |
| JP2006516604A (ja) | 2003-01-31 | 2006-07-06 | ファイザー・プロダクツ・インク | ５ｈｔ７アンタゴニストおよび逆アゴニスト |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| GB0316128D0 (en) | 2003-07-10 | 2003-08-13 | Univ Aston | Novel sulfonamide compounds |
| JP4679517B2 (ja) | 2003-07-23 | 2011-04-27 | エグゼリクシス， インコーポレイテッド | 薬剤としてのアゼピン誘導体 |
| MXPA06003150A (es) | 2003-09-17 | 2006-08-31 | Johnson & Johnson | Compuestos heterociclicos fusionados. |
| AU2004276341B2 (en) * | 2003-09-23 | 2011-04-14 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrrole derivatives as protein kinase inhibitors |
| CA2538023A1 (en) | 2003-09-24 | 2005-04-07 | Combinatorx, Incorporated | Therapeutic regimens for administering drug combinations |
| WO2005056056A2 (en) | 2003-12-15 | 2005-06-23 | H. Lundbeck A/S | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |
| US20050232986A1 (en) | 2003-12-17 | 2005-10-20 | David Brown | Dosage form containing promethazine and another drug |
| US20090227562A1 (en) | 2004-08-10 | 2009-09-10 | Pfizer Inc. | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor |
| US20060037652A1 (en) | 2004-08-23 | 2006-02-23 | Ranco Incorporated Of Delaware | Reversing valve assembly with improved pilot valve mounting structure |
| US20060194837A1 (en) | 2004-12-17 | 2006-08-31 | Carruthers Nicholas I | Tetrahydroisoquinoline compounds |
| JP2008546711A (ja) | 2005-06-17 | 2008-12-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｃｎｓ障害の処置のためのヘキサヒドロ−ピロロ−イソキノリン化合物 |
| ES2314933T3 (es) | 2005-06-17 | 2009-03-16 | Janssen Pharmaceutica Nv | Compuestos de naftiridina. |
| KR101353268B1 (ko) | 2005-08-04 | 2014-02-06 | 얀센 파마슈티카 엔.브이. | 세로토닌 수용체 모듈레이터로서의 피리미딘 화합물 |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| KR20080109841A (ko) * | 2006-03-10 | 2008-12-17 | 뉴로젠 코포레이션 | 피페라지닐 옥소알킬 테트라히드로이소퀴놀린 및 관련유사체 |
| CN101479252B (zh) | 2006-05-05 | 2014-01-29 | 詹森药业有限公司 | 用于制备含吡唑的化合物的方法 |
| EP2049473A2 (en) | 2006-06-29 | 2009-04-22 | Janssen Pharmaceutica N.V. | Substituted benzyl amine compounds |
| EP2049466A1 (en) | 2006-06-29 | 2009-04-22 | Janssen Pharmaceutica N.V. | Butyl and butynyl benzyl amine compounds |
| CN101511790A (zh) | 2006-06-29 | 2009-08-19 | 詹森药业有限公司 | 取代的氨基甲基苯甲酰胺化合物 |
| WO2008064036A1 (en) | 2006-11-16 | 2008-05-29 | Janssen Pharmaceutica N.V. | Substituted phenyl propyl amines as histamine h3 receptor and serotonin transporter modulators |
-
2004
- 2004-09-15 MX MXPA06003150A patent/MXPA06003150A/es active IP Right Grant
- 2004-09-15 CN CN201410027820.XA patent/CN103788089A/zh active Pending
- 2004-09-15 DE DE602004019118T patent/DE602004019118D1/de not_active Expired - Lifetime
- 2004-09-15 CA CA2539426A patent/CA2539426C/en not_active Expired - Fee Related
- 2004-09-15 PT PT04816874T patent/PT1668014E/pt unknown
- 2004-09-15 AU AU2004283196A patent/AU2004283196B2/en not_active Ceased
- 2004-09-15 ES ES04816874T patent/ES2319539T3/es not_active Expired - Lifetime
- 2004-09-15 SI SI200431089T patent/SI1668014T1/sl unknown
- 2004-09-15 EA EA200801812A patent/EA200801812A1/ru unknown
- 2004-09-15 EP EP04816874A patent/EP1668014B1/en not_active Expired - Lifetime
- 2004-09-15 WO PCT/US2004/030190 patent/WO2005040169A2/en not_active Ceased
- 2004-09-15 JP JP2006526993A patent/JP5069907B2/ja not_active Expired - Fee Related
- 2004-09-15 PL PL04816874T patent/PL1668014T3/pl unknown
- 2004-09-15 DK DK04816874T patent/DK1668014T3/da active
- 2004-09-15 KR KR1020067007322A patent/KR101151653B1/ko not_active Expired - Fee Related
- 2004-09-15 SG SG200807152-4A patent/SG146683A1/en unknown
- 2004-09-15 EA EA200600433A patent/EA010905B1/ru unknown
- 2004-09-15 AT AT04816874T patent/ATE420881T1/de active
- 2004-09-15 US US10/941,664 patent/US7402680B2/en active Active
- 2004-09-15 NZ NZ545836A patent/NZ545836A/en not_active IP Right Cessation
- 2004-09-15 BR BRPI0414541A patent/BRPI0414541B8/pt not_active IP Right Cessation
- 2004-09-16 TW TW093128049A patent/TWI345565B/zh not_active IP Right Cessation
- 2004-09-17 AR ARP040103363A patent/AR047218A1/es active IP Right Grant
-
2006
- 2006-03-09 IS IS8348A patent/IS2756B/is unknown
- 2006-03-13 IL IL174283A patent/IL174283A/en active IP Right Grant
- 2006-03-17 CR CR8302A patent/CR8302A/es unknown
- 2006-03-17 EC EC2006006436A patent/ECSP066436A/es unknown
- 2006-04-20 NI NI200600094A patent/NI200600094A/es unknown
-
2007
- 2007-10-25 US US11/924,277 patent/US7579470B2/en not_active Expired - Lifetime
-
2009
- 2009-04-10 CY CY20091100428T patent/CY1109416T1/el unknown
- 2009-04-20 CL CL2009000943A patent/CL2009000943A1/es unknown
- 2009-07-02 US US12/496,866 patent/US7897771B2/en not_active Expired - Fee Related
- 2009-09-11 US US12/557,661 patent/US8618288B2/en not_active Expired - Fee Related
-
2010
- 2010-10-25 US US12/911,523 patent/US20110040088A1/en not_active Abandoned
- 2010-11-02 IL IL209082A patent/IL209082A0/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047218A1 (es) | Compuestos heterociclicos fusionados que contienen pirrol y pirazol,utiles en el tratamiento de enfermedades mediadas por serotonina, composiciones farmaceuticas que los contienen, usos y metodos de preparacion | |
| AR129635A2 (es) | Moduladores de tetrahidropiridopirazina de gpr6 | |
| AR065354A1 (es) | Derivados de 2-aminopirimidina, un metodo para su preparacion, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de histamina h4. | |
| AR075051A1 (es) | Compuestos antidiabeticos que contienen ftalazina | |
| AR045386A1 (es) | [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
| AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR036191A1 (es) | Compuestos antagonistas de receptores y5 del neuropeptido y, una composicion farmaceutica, un procedimiento para preparar dicha composicion y el uso de dichos compuestos, solos o en combinacion para la preparacion de una composicion farmaceutica | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR112468A1 (es) | Carboxamidas como inhibidores de proteasa específicos de ubiquitina | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
| AR075854A1 (es) | Inhibidores de beta- secretasa | |
| AR078776A1 (es) | Derivados de (1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-il)-fenilo | |
| CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
| AR045388A1 (es) | Inhibidores del c-kit imidazopiridinicos n3-sustituidos | |
| AR059428A1 (es) | Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende. | |
| AR094300A1 (es) | Derivados de quinolonas | |
| AR069509A1 (es) | Pirido (3,2-e) pirazinas, su procedimiento de preparacion y uso como inhibidores de fosfodiesterasa 10 | |
| AR060903A1 (es) | Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp | |
| AR048939A1 (es) | Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios. | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
| AR057034A1 (es) | Metodos para purificar tigeciclina | |
| AR079260A1 (es) | Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos | |
| AR116464A1 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |